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Abstract 
 
The release of the proinflammatory factors is enhanced with increased fat mass, linking adipose 
tissue inflammation to metabolic dysfunction. Vitamin D3 is a pleiotropic hormone with a range of 
functions in addition to calcium and bone metabolism. Low vitamin D3 status has been linked to a 
number of diseases including obesity and metabolic syndrome. Previous studies from our group 
and others have shown the anti-inflammatory property of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
in adipose tissue in obesity. However, administration of 1,25(OH)2D3 at a supraphysiological dose 
can lead to hypercalcemia and this hampers its use as a safe course of treatment. The development 
of the 1,25(OH)2D3 analogues that have immunomodulatory activity with minimal calcemic effects 
could be beneficial in clinical practice. ZK159222 and ZK191784 are vitamin D3 analogues known 
to act on the vitamin D receptors but their effects on adipose tissue particularly the local 
inflammation are not known. This study investigated whether ZK159222 and ZK191784 are able to 
modulate the inflammatory response and the signalling pathways involved in human adipocytes. 
Like 1,25(OH)2D3, treatment with ZK159222 and ZK191784 significantly reduced macrophage-
stimulated activation of NF-κB signalling, upregulating IκBα expression and reducing p65 
phosphorylation. The phosphorylation of p38 mitogen-activated protein kinase (MAPK) stimulated 
by macrophage-derived factors was also inhibited by the two compounds. Additionally, 
macrophage-induced release of the key proinflammatory cytokine/chemokines (IL-6, IL-8, MCP-1 
and RANTES) was markedly decreased by the treatment with ZK159222 and ZK191784. Taken 
together, both 1,25(OH)2D3 analogues have potent anti-inflammatory effects in human adipocytes. 
These actions are probably mediated by preventing the activation of the NF-κB and MAPK 
signalling pathways. The data suggests that the two 1,25(OH)2D3 analogues may serve as a 
potential therapeutic option to have anti-inflammatory effects in adipose tissue in obesity. 
 
 
 
 
 
 
 
 
 
 
Introduction 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the bioactive form of  vitamin D3, is a pleiotropic 
hormone with a wide range of functions in addition to its classical role in bone and calcium 
metabolism (Boyle, Gray et al. 1972; Mellanby 1976). It is estimated that vitamin D3 deficiency 
affects approximately one billion people worldwide (Holick 2007). vitamin D3 deficiency has 
also been linked to the metabolic disorders, including obesity and insulin resistance (Chiu, Chu 
et al. 2004; Barchetta, Angelico et al. 2011; Olson, Maalouf et al. 2012). Data from clinical 
studies have shown that low vitamin d3 status are common in obese patients (Goldner, Stoner 
et al. 2008; Brock, Huang et al. 2010; Fish, Beverstein et al. 2010). obesity is now known to 
be associated with a low-grade chronic inflammation, characterised by a significant increase 
in accumulation of macrophages and other immune cells in adipose tissue, the activation of 
inflammatory signalling (i.e. NF-κB and MAPK) pathways and the release of proinflammatory 
cytokine/chemokines (i.e. TNFα, IL-6, IL-8 and monocyte chemotactic protein-1 (MCP-1)). 
Adipose tissue inflammation in obesity is considered as a driving force in the pathogenesis of 
insulin resistance and type 2 diabetes (Fontana, Eagon et al. 2007; Bourlier and Bouloumie 
2009; Lolmede, Duffaut et al. 2011; Gao, Madi et al. 2014). Recent studies from our group and 
others have demonstrated that 1,25(OH)2D3 has potent anti-inflammatory effects in adipose 
tissue, such as inhibiting the production of proinflammatory cytokines/chemokines by 
preadipocytes and adipocytes, and reducing macrophage infiltration (Lorente-Cebrian, 
Eriksson et al. 2012; Marcotorchino, Gouranton et al. 2012; Ding, Wilding et al. 2013; Gao, 
Trayhurn et al. 2013). A main concern of using 1,25(OH)2D3 for treatment is the possible 
disruption of calcium homeostasis inducing hypercalcemia (Smith, Johnson et al. 1999; 
Slatopolsky and Brown 2002). Furthermore, circulating levels of 1,25(OH)2D3 has been shown 
to be negatively correlated with coronary calcification (Watson, Abrolat et al. 1997). 1,25(OH)2D3 
is known to exert a wide range of effects, which can be classified as genomic and non-genomic. 
The genomic effects of 1,25(OH)2D3 is characterised by its binding to the vitamin D receptor 
(VDR) in the cytoplasm, nuclear translocation of the liganded receptor and interaction with 
vitamin D response elements in the promoter region of genes, leading to changes in gene 
expression within hours (Haussler, Jurutka et al. 2011). Its non-genomic effects include rapid 
changes in intracellular calcium concentrations, membrane phospholipid metabolism and 
activation of protein kinases, which is involved in several signal transduction cascades, and 
the non-genomic effects of 1,25(OH)2D3 may be VDR independent (Kajikawa, Ishida et al. 
1999; Mizwicki and Norman 2009; Menegaz, Barrientos-Duran et al. 2010; Hii and Ferrante 
2016). Despite the potential therapeutic effects of 1,25(OH)2D3 in vitro, its clinical use could 
be limited mostly due to unwanted hypercalcemic effects. 
 
The development of 1,25(OH)2D3 analogues, with low calcemic effects but selective actions on 
VDR-mediated gene transcription, may offer an attractive solution in clinical practice. ZK159222 
and ZK191784 are the 1,25(OH)2D3 analogues, both of which act on the vitamin D receptors 
(Carlberg 2003; Nijenhuis, van der Eerden et al. 2006). ZK159222 is a partial antagonist of VDR, 
characteristised by a long butyl ester at the C25 position of the side chain (Carlberg 2003). In 
contrast to the natural hormone, ZK159222 appears to prevent the interaction of VDR with 
coactivators (Toell, Gonzalez et al. 2001). However, like 1,25(OH)2D3, the binding of ZK159222 to 
the VDR can induce a dissociation of the majority of the VDR-corepressor complexes (Polly, 
Herdick et al. 2000). These observations suggest that the antagonistic quality of ZK159222 is 
achieved by stabilising the VDR in a conformation that blocks coactivator to interact with vitamin D 
response elements (VDREs), without affecting the normal VDR-corepressor dissociation (Toell, 
Gonzalez et al. 2001). It has been shown that ZK159222 is not a complete antagonist as it still 
retains approximately 20% of the agonistic ability of 1,25(OH)2D3 (Toell, Gonzalez et al. 2001; 
Vaisanen, Perakyla et al. 2002). However, whether ZH159222 has immunomodulatory activity is 
largely unknown. 
 
ZK191784 is characterised by an altered side chain structure containing a 22,23-double bond, 24R-
hydroxy group, 25-cyclopropyl ring, and 5-butyloxazole-group (Nijenhuis, van der Eerden et al. 
2006). ZK191784 has been reported to competitively binds to the VDR with a similar affinity as 
1,25(OH)2D3 (Zugel, Steinmeyer et al. 2002). Unlike 1,25(OH)2D3, ZK191784 dose not stimulate 
intestinal Ca2+ absorption and reduces renal Ca2+ excretion that it has less calcemic effects than 
1,25(OH)2D3 (Nijenhuis, van der Eerden et al. 2006). Studies in vivo and in vitro have suggested 
that ZK191784 exhibit immunomodulatory activity. ZK191784 has been shown to have therapeutic 
potential in T cell-mediated immune disorders with a 100-fold lower hypercalcemic effect in 
comparison with 1,25(OH)2D3 in rats (Zugel, Steinmeyer et al. 2002). In experimental colitis in mice, 
ZK191784 treatment ameliorated acute and chronic intestinal inflammation probably by its 
immunosuppressive effects on mucosal dendritic cells without exhibiting calcemic effects (Strauch, 
Obermeier et al. 2007). Moreover, ZK191784 downregulated adhesion molecules and MMPs 
production in colonic biopsies of patient with inflammatory bowel diseases (Martinesi, Ambrosini et 
al. 2014).  
 
Although ZK159222 and ZK191784 have congruent effects on the VDR, their roles in adipose tissue 
particularly the local inflammation which often occurs in obesity are not known. This study was 
therefore to investigate whether the two 1,25(OH)2D3 analogues modulate the inflammatory 
responses and the signalling pathways involved in human adipocytes. Their effects were compared 
to the action of the natural ligand, 1,25(OH)2D3.  
 
Materials and methods 
Culture of adipocytes 
Human preadipocytes derived from subcutaneous adipose tissue of a female Caucasian subject 
(BMI 21 kg/m2; age 44 yr) were obtained from PromoCell (Heidelberg, Germany). Cells were 
seeded at 40,000/cm2 and grown in 24-well plates in preadipocyte growth medium, containing 
DMEM-Ham’s F-12 (1:1, vol/vol) and supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 0.25 μg/ml amphotericin B (Lonza, Twekesbury, UK), at 37°C in a humidified 
atmosphere of O2:CO2 (95:5%). At confluence, cells were induced to differentiate at day 0 by 
incubation for 3 days in Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F12 (1:1 ratio) 
medium which contained 32 μM biotin, 1μM dexamethasone, 200 μM 3-isobutyl-1-methyl-xanthine, 
100 nM insulin, 11 nM L-Thyroxine (all from Sigma, Poole, Dorset, UK), 8 μM rosiglitazone 
(GlaxoSmithKline, Uxbridge, UK), 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml 
amphotericin B. After induction, cells were cultured in maintenance medium containing 3 % foetal 
calf serum (FCS; Sigma), 100 nM insulin, 32 μM biotin and 1 μM dexamethasone until fully 
differentiated. Differentiation into mature adipocytes was confirmed by observing the accumulation 
of lipid droplets under the microscope. 
 
Culture of THP-1 macrophages 
Human THP-1 myelomonocytic cell line (Health Protection Agency Culture Collections, Porton 
Down, Salisbury UK) was used. THP-1 monocytes (1×106 cells/ml) were cultured in a 150 cm2 flask 
in Roswell Park Memorial Institute (RPMI-1640) medium, containing 10% FCS, 100 U/ml penicillin 
and 100 μg/ml streptomycin, at 37°C in a humidified atmosphere of O2:CO2 (95:5%). THP-1 
monocytes were differentiated into macrophages with 100 nM phorbol 12-myristate 13-acetate 
(PMA) (Sigma) for 48 h. The medium was replaced with PMA-free and FCS-free RPMI-1640 
medium for 24 h. This medium as macrophage-conditioned (MC) medium was collected, filtered 
through a 0.22µm filter and stored at -80°C for later use. 
Cell treatment 
ZK159222 and ZK191784, VDR ligands (Herdick, Steinmeyer et al. 2000; Herdick, Steinmeyer et 
al. 2000; Zugel, Steinmeyer et al. 2002; Schmitz, Hackethal et al. 2015), were a generous gift from 
Bayer Pharma AG (Berlin, Germany). Differentiated adipocytes (Day 11) were grouped and 
incubated with adipocytes maintenance media, 10-8M of 1,25(OH)2D3 (Sigma) , ZK159222 (10-8M 
or 10-6M) and ZK191784 (10-8M or 10-6M) for 48 h. The cell culture medium was replaced with RPMI 
(control), MC medium (MC), MC medium with 1,25(OH)2D3 (10-8M), MC medium with ZK159222 
(10-8M or 10-6M) and MC medium with ZK191784 (10-8M or 10-6M) for 24 h. The culture medium 
and cell lysates were collected and stored at -80°C until later analyses. 
Western blotting 
Cell lysates were prepared by lysing cells in lysis buffer (50 mM Tris-HCl pH 6.7, 10% glycerol, 4% 
SDS, 2% 2-mer-capoethanol) with protease inhibitor cocktail and phosphatase inhibitors (Sigma). 
Protein concentrations of the lysates were then measured by the bicinchoninic acid method. Protein 
samples were separated on 10% Tricine-SDS polyacrylamide gels (Mini Protean Tetra, Bio-Rad, 
Hemel Hempstead, UK) and transferred to nitrocellulose membranes at 100v for 1 h. Protein marker 
was used on one lane for identification of target bands. The membranes were blocked with 5% BSA 
in Tris-buffered saline (TBS) and 0.1% Tween-20 for 1 h at room temperature. The membranes 
were then incubated with the primary antibody, including Ικβα, phosphorylated NFκB p65 and 
phosphorylated p38 MAPK (all from New England Biolabs, Hitchin, UK) overnight at 1:1000 dilution 
at 4°C. The membranes were washed in phosphate-buffered saline with 0.1% Tween-20 and 
subsequently incubated with a HRP-conjugated secondary antibody (New England Biolabs). 
Chemiluminescent signals were evaluated and quantified using a SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, US) using the ChemiDoc XRS+ System (Bio-
Rad). The membranes were further probed for vinculin or GAPDH (both from Abcam, Cambridge, 
UK) as a loading control. 
Measurement of cytokine/chemokine release 
The release of IL-6, IL-8, MCP-1 and RANTES by adipocytes and THP-1 macrophages was 
measured as protein concentrations in culture medium, using the DuoSet ELISA Development kits 
(R&D Systems, Abingdon, UK). 
Cytotoxicity evaluation 
Adipocyte viability after treatment with various compounds was assessed as release of lactate 
dehydrogenase (LDH) into the cell culture medium, using a colourimetric cytotoxicity detection kit 
(Roche Diagnostics GmbH, Mannheim, Germany). LDH levels were measured at room temperature 
by a spectrophotometer at 492 nm with a reference wavelength of 620 nm. 
Statistical analysis 
All results are presented as means ± standard error of mean (SEM). Statistical differences among 
groups were assessed by one-way ANOVA coupled with Bonferroni’s t-test. Differences were 
considered as statistically significant when P value < 0.05. Statistical tests were performed using 
Graphpad Prism version 5.03 and SPSS(PASW), release version 19.0. 
 
Results 
ZK 159222 and ZK191784 inhibit macrophage-induced activation of NF-κB in human 
adipocytes 
This set of experiments examined whether ZK159222 and ZK191784 have similar effects to 1,25-
dihydroxyvitamin D3 on macrophage-induced NF-κB activation in adipocytes. As shown by Figure.1, 
treatment with 1,25(OH)2D3 led to an increase in IκBα expression (P = 0.003) in adipocytes 
stimulated with MC medium. ZK159222 treatment reversed MC medium-induced downregulation 
of IκBα in a dose-dependent manner, inducing a 3.9-fold at 10-8M although this was not statistically 
significant (P = 0.148) and a 7.4-fold increase at 10-6M (P = 0.002). Compared to 1,25(OH)2D3, the 
effect of ZK159222 at 10-8M was less potent but it had a similar effect to 10-8M 1,25(OH)2D3 at 10-
6M. 
ZK159222 also downregulated the induction of phosphorylated NF-κB p65 expression by MC 
medium. While 1,25(OH)2D3 (10-8M) decreased phosphorylated NF-κB p65 by 67% (P = 0.011), 
ZK159222 significantly reversed MC medium-induced upregulation of phosphorylated NF-κB p65 
by 90% at 10-8M (P = 0.002) and 91% at 10-6M (P = 0.001) compared to adipocytes that received 
treatment with MC medium only. ZK159222 appeared to have a greater effect in reducing 
phosphorylated NF-κB p65 compared with 1,25(OH)2D3, although there were no statistically 
significant differences among three groups that received treatment with 1,25(OH)2D3 or its 
analogues (Figure 2). 
As shown by Figure 3, ZK191784, another analogue of 1,25(OH)2D3, displayed similar effects as 
1,25(OH)2D3. Like 1,25(OH)2D3 which elicited a 9.1-fold increase in IκBα expression (P = 0.004), 
ZK191784 treatment dose-dependently reversed macrophage-induced downregulation of IκBα, 
leading to a 5.4-fold increase at 10-8M although this was not statistically significant (P = 0.11), and 
a 10-fold increment at 10-6M (P = 0.002). There were no statistically significant differences among 
three groups that received treatment with vitamin D3 or its analogues. 
Similar to 1,25(OH)2D3, ZK191784 also downregulated protein expression of phosphorylated NF-
κB p65 in adipocytes stimulated with MC medium (Figure 4). While 1,25(OH)2D3 decreased 
phosphorylated NF-κB p65 by 41% (P < 0.001), ZK191784 reduced phosphorylated NF-κB p65 by 
57% at 10-8M (P < 0.001) and 59% at 10-6M (P < 0.001) compared with adipocytes that received 
treatment with MC medium only. Compared to 1,25(OH)2D3 (10-8M), ZK191784 showed a greater 
potency in reducing phosphorylated NF-κB p65 at both concentrations (P = 0.02 for 10-8M, P = 
0.009 for 10-6M). 
ZK 159222 and ZK191784 inhibit macrophage-induced expression of p38 MAPK in 
human adipocytes 
Since both vitamin D3 compounds modulate the activation of NF-κB, we next examined whether 
ZK159222 and ZK191784 have effects on the MAPK signalling pathway in adipocytes. As shown 
by Figure 5A, similar to 1,25(OH)2D3 which caused a 42% decrease in phosphorylated p38 MAPK 
(P = 0.002), ZK159222 partially reversed macrophage-induced upregulation of phosphorylated p38 
MAPK in a  dose-dependent manner, with a 27% decrease at 10-8M (P = 0.03) and a 77% decrease 
at 10-6M (P < 0.001). Compared to 1,25-dihydroxyvitamin D3, the level of reduction in 
phosphorylated p38 MAPK by ZK159222 was not significantly different at 10-8M (P = 0.45) but the 
inhibitory effect was enhanced at 10-6M (P=0.006). 
Similar to 1,25(OH)2D3, ZK191784 downregulated phosphorylated p38 MAPK expression in 
adipocytes stimulated with MC medium (Figure 5B). While 1,25(OH)2D3 decreased phosphorylated 
p38 MAPK by 57% (P < 0.001), ZK191784 dose-dependently reversed upregulation of 
phosphorylated p38 MAPK by MC medium, inducing a 55% decrease at 10-8M (P < 0.001) and a 
94% at 10-6M (P < 0.001). At similar concentrations (10-8M), there was no significant difference in 
the potency of inhibition on phosphorylated p38 MAPK between ZK191784 and 1,25(OH)2D3 (P > 
0.05) but at higher dose (10-6M) the inhibitory effect of  ZK191784 was greater (P = 0.002). 
ZK159222 and ZK191784 inhibit macrophage-induced secretion of IL-6, MCP-1, IL-8 and 
RANTES by human adipocytes 
To further study the downstream effects of inhibiting NF-κB and MAPK signalling by ZK159222 and 
ZK191784, we examined the release of some key cytokine and chemokines in adipocytes. As 
shown by Figure 6, MC medium-induced IL-6 secretion by adipocytes was reduced 36% following 
the treatment with 1,25(OH)2D3 compared to adipocytes incubated in MC medium alone (P < 0.001). 
10-8M and 10-6M of ZK159222 reduced macrophage-induced IL-6 release by 52% and 71% 
respectively (both P < 0.001). 10-8M and 10-6M of ZK191784 reduced IL-6 release from adipocytes 
by 35% and 54% respectively (both P < 0.001). Furthermore, the inhibitory effect of 10-6M 
ZK159222 on IL-6 production was stronger compared with 10-8M of 1,25(OH)2D3 (54% decrease, P 
< 0.001). 
In Figure 6, MC medium-induced MCP-1 secretion by adipocytes was reduced 47% with the 
treatment of 1,25(OH)2D3 compared to adipocytes incubated in MC medium alone (P = 0.001). 
MCP-1 release was reduced by 78% and 77% by adipocytes treated with 10-8M and 10-6M of 
ZK159222 (both P < 0.001). Similarly, MCP-1 release by adipocytes treated with 10-8M and 10-6M 
of ZK191784 was reduced by 77% and 88% respectively (both P < 0.001). Of the compounds 
tested, only 10-6M of ZK191784 showed a greater effect in lowering MCP-1 secretion compared 
with 10-8M 1,25(OH)2D3 (P < 0.01). 
Furthermore, MC medium-stimulated IL-8 secretion by adipocytes was reduced by 31% with the 
treatment of 1,25(OH)2D3 (P < 0.001). Treatment with 10-8M and 10-6M of ZK159222 reduced IL-8 
release by 53% and 64% respectively (both P < 0.001). Treatment with 10-8M and 10-6M of 
ZK191784 reduced IL-8 release by 49% and 65% in a dose-dependent manner (both P < 0.001). 
Compared with 10-8M of 1,25(OH)2D3, IL-8 secretion was significantly lower from adipocytes treated 
with ZK159222 and ZK191784 at all doses (P < 0.001).  
Finally, MC medium-induced RANTES secretion by adipocytes treated with 1,25(OH)2D3  was 
attenuated (by 96%, P < 0.001). Treatment with 10-8M and 10-6M of ZK159222 markedly reduced 
macrophage-induced release of RANTES (by 85% and 91% respectively, both P = 0.002). Similarly, 
treatment with 10-8M and 10-6M of ZK191784 significantly reduced RANTES release by adipocytes 
by 82% (P = 0.004) and 93% (P = 0.005), respectively. Compared with 10-8M of 1,25(OH)2D3, there 
were no significant differences in RANTES secretion by ZK159222 and ZK191784 treatment at all 
doses. 
Effects of MC medium, 1,25-dihydroxyvitamin D3, ZK159222 and ZK191784 on cell viability 
Cytotoxicity of the compounds (MC medium, 1,25(OH)2D3, ZK159222 and ZK191784) used in this 
study were examined by the measurement of LDH release into cell culture media. As shown by 
Figure 7, there was no significant difference between the control and the treatment groups. 
 
Discussion 
Chronic inflammation has an important role in the pathogenesis of obesity and its related metabolic 
disorders (Gustafson, Hammarstedt et al. 2007; Gregor and Hotamisligil 2011). Adipose tissue as 
a major endocrine organ releases a wide range of protein factors, including cytokines/chemokines 
(i.e. IL-1, IL-6, IL-8 and MCP-1) (Fain 2006). The release of the proinflammatory factors is enhanced 
with increased fat mass,  linking adipose tissue inflammation to metabolic dysfunction (Hotamisligil 
2006). Previous studies from our group and others have provided evidence for the anti-inflammatory 
property of 1,25(OH)2D3 in adipose tissue, which was demonstrated by reduced proinflammatory 
response in adipocytes stimulated by macrophage-derived factors, cytokines and LPS as well as 
in adipose tissue of obese mice induced by high-fat diet (Lira, Rosa et al. 2011; Lorente-Cebrian, 
Eriksson et al. 2012; Mutt, Karhu et al. 2012; Ding, Wilding et al. 2013; Gao, Trayhurn et al. 2013). 
However, these studies suggest that supraphysiological doses of 1,25(OH)2D3 are required to have 
a significant effect in adipose tissue. As using high doses of 1,25(OH)2D3 has been linked to the 
increased risk of hypercalcemic side effects, (Huckins, Felson et al. 1990; Nijenhuis, van der 
Eerden et al. 2006), it is unlikely that 1,25(OH)2D3 can be used as a sustainable treatment 
particularly for those with renal insufficiency. The analogues of 1,25(OH)2D3 with low calcemic 
effects may offer an alternative solution in clinical practice. A number of 1,25(OH)2D3 analogues 
have been developed with the purpose of improving the biological profile of the natural hormone 
for potential therapeutic value (Carlberg 2003). The current study therefore investigated whether 
the two 1,25(OH)2D3 analogues, ZK159222 and ZK191784, have modulatory effects on adipose 
tissue inflammation in vitro.  
 
In the present study, we demonstrate for the first time the anti-inflammatory actions of the two 
1,25(OH)2D3 analogues in human adipocytes. Our study initially examined the effects of ZK159222 
and ZK191784 on the NF-κB signalling pathway. The transcription factor NF-κB is a key regulator 
of inflammatory gene expression and its activity is enhanced in adipose tissue during obesity 
(Chiang, Bazuine et al. 2009; Ding, Gao et al. 2012). NF-κB is activated by the degradation of IκBα 
protein, allowing nuclear translocation of the p65 subunit of NF-κB (Tak and Firestein 2001). In the 
current study, ZK159222 was able to reverse IκBα expression suppressed by MC medium in 
adipocytes although to a lesser extent when compared to 1,25(OH)2D3 in equimolar concentrations. 
In addition, both doses of ZK159222 (10-8M and 10-6M) inhibited macrophage-induced 
phosphorylation of NF-κB p65 and this effect appeared to be stronger in comparison with 
1,25(OH)2D3 (Figure. 2). Although ZK159222 is an antagonist of VDR being used to study the effect 
of full VDR activation by 1,25(OH)2D3, it still has some agonistic potential of 1,25(OH)2D3 (Herdick, 
Steinmeyer et al. 2000; Vaisanen, Perakyla et al. 2002). However, little is known whether ZK159222 
has immunomodulatory property. A previous study has shown that ZK159222 inhibited 
1,25(OH)2D3-induced NO production in porcine aortic endothelial cells (Molinari, Rizzi et al. 2013). 
In the present study, ZK159222 enhanced IκBα stability supporting the notion that VDR binding 
stabilises IκBα in adipocytes. Furthermore, NF-κB p65 phosphorylation has been shown to be 
mediated by intracellular calcium levels (Sun and Carpenter 1998; Thuringer, Hammann et al. 2011) 
and 1,25(OH)2D3 is also a non-genomic enhancer. As ZK159222 is not known to have non-genomic 
effect, it may have greater potency in preventing the phosphorylation of NF-κB p65. In the present 
study, we have also shown that ZK191784 can reverse IκBα expression inhibited by macrophage-
derived factors in adipocytes. Moreover, ZK191784 at both doses (10-8M and 10-6M) attenuated 
upregulation of phosphorylated NF-κB p65 stimulated by MC medium, and this effect was stronger 
than 1,25(OH)2D3 (Figure. 4). Taken together, our data suggest that ZK159222 and ZK191784 have 
strong inhibitory effects on macrophage-induced activation of NF-κB signalling in human 
adipocytes.  
 
The activation of the MAPK signalling is also involved in the signal transduction of inflammatory 
mediators leading to inflammatory response in several cell types (Zhang, Leung et al. 2012) 
including preadipocytes and adipocytes (Gao, Trayhurn et al. 2010; Ding, Wilding et al. 2013). In 
this study, we have shown that ZK159222 and ZK191784 are able to inhibit the activation of the 
MAPK signalling in human adipocytes. Both 1,25(OH)2D3 analogues inhibited phosphorylation of 
p38 MAPK in a dose-dependent manner. Moreover, their inhibitory effect was comparable to that 
of 1,25(OH)2D3 (Figure. 5). Therefore, the MAPK signalling pathway could be potential target of the 
1,25(OH)2D3 analogues for reducing inflammatory response in adipose tissue.  
 
To further study the downstream effects of ZK159222 and ZK191784 on adipose tissue 
inflammation, we have examined the release of the key proinflammatory cytokine and chemokines 
by adipocytes upon macrophage stimulation.  IL-6, a major cytokine and expressed by adipocytes, 
is critically involved in obesity related inflammation and insulin resistance (Rotter, Nagaev et al. 
2003; Kristiansen and Mandrup-Poulsen 2005).  In the present study, ZK159222 and ZK191784 
markedly reduced protein release of IL-6 by adipocytes as the natural hormone 1,25(OH)2D3 
(Figure. 6). Although the effect of the two compounds on IL-6 release was unknown previously, 
ZK191784 has been shown to inhibit LPS-induced secretion of cytokine IL-12 and TNF-α by human 
PBMCs, with a similar potency as 1,25(OH)2D3 (Zugel, Steinmeyer et al. 2002). MCP-1 is a 
chemokine with a chemotactic activity for monocytes and its overexpression enhances macrophage 
infiltration and insulin resistance (Kamei, Tobe et al. 2006; Kanda, Tateya et al. 2006). The current 
study has shown that ZK159222 and ZK191784 markedly reduced MCP-1 secretion (77-88%) 
elicited by MC medium to an extent similar to the treatment with 1,25(OH)2D3. Moreover, the higher 
dose (10-6M) of ZK191784 had strongest inhibitory effect on MCP-1 release by adipocytes (Figure. 
6). IL-8 as a neutrophil chemotactic factor has been shown to induce chemotaxis in other cell types 
including macrophages (Waugh and Wilson 2008), and it has been reported that lack of IL-8 
receptor reduced macrophage infiltration in adipose tissue (Neels, Badeanlou et al. 2009). In the 
present study, ZK159222 and ZK191784 decreased macrophage-induced IL-8 release (up to 65%), 
with a greater efficacy compared to 1,25(OH)2D3. Chemokine RANTES is another key player in 
obesity-associated inflammation in adipose tissue. RANTES stimulates monocyte migration and 
macrophage survival in human adipose tissue; its expression in adipose tissue is increased in 
obese patients (Keophiphath, Rouault et al. 2010). Like 1,25(OH)2D3, both analogues significantly 
reduced macrophage-induced RANTES secretion (82-93%) by adipocytes. Taken together, our 
results show that ZK159222 and ZK191784 produced comparable effects to 1,25(OH)2D3 in 
reducing the production of the cytokine/chemokines by adipocytes. It is suggested that both 
compounds have anti-inflammatory actions similar to the natural ligand in adipose tissue.  
In conclusion, we have demonstrated that ZK159222 and ZK191784 possess anti-inflammatory 
properties in adipose tissue. Both 1,25(OH)2D3 analogues powerfully inhibit macrophage-induced 
secretion of the proinflammatory cytokine and chemokines by adipocytes. This effect is probably 
via preventing the activation of the NF-κB and MAPK signalling pathways. Our study suggests that 
the 1,25(OH)2D3 analogues may serve as a potential option to enhance VDR-mediated anti-
inflammatory effects in adipose tissue in obesity. 
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Legends 
Figure 1. ZK159222 reverses macrophage-inhibited IκBα expression by adipocytes. 
Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or 
ZK159222 (10-8M and 10-6M) for 48 h. Adipocyte medium was then replaced with RPMI-1640 
medium (control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M) or ZK159222 (10-8M and 
10-6M) for 24 h. IκBα protein content was determined by western blotting and quantified by 
densitometry. Data are means ± SEM, normalised to vinculin levels, n=3 per group. **P  < 0.01 vs 
MC group.  
Figure 2. ZK159222 inhibits macrophage-induced expression of NF-κB p65 by adipocytes. 
Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or 
ZK159222 (10-8M and 10-6M) for 48 h. Adipocyte medium was then replaced with RPMI-1640 
medium (control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M) or ZK159222 (10-8M and 
10-6M) for 24 h. Phos-NF-κB p65 protein content was analysed by western blotting and quantified 
by densitometry. Data are means ± SEM, normalised to vinculin levels, n=3 per group. *P  < 0.05, 
**P  < 0.01 vs MC group . 
Figure 3. Effects of ZK191784 on macrophage-inhibited expression of IκBα by adipocytes. 
Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or 
ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 medium 
(control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) 
for 24 h. IκBα protein content was analysed by western blotting and quantified by densitometry. 
Data are means ± SEM, normalised to vinculin levels, n=3 per group. **P  < 0.01 vs MC group.  
Figure 4. Effects of ZK191784 on macrophage-induced expression of NF-κB p65 by 
adipocytes. Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 
(10-8M) or ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 
medium (control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 
10-6M) for 24 h. Phos-NF-κB p65 protein content was analysed by western blotting and quantified 
by densitometry. Data are means ± SEM, normalised to vinculin levels, n=3 per group. **P  < 0.05, 
**P  < 0.01, ***P  <  0.001 vs MC group.  
Figure 5. ZK159222 and ZK191784 inhibit macrophage-induced expression of Phos-p38 
MAPK by adipocytes. Differentiated adipocytes were incubated with maintenance medium, 1,25-
(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with 
RPMI-1640 medium (control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M), ZK159222 
(10-8M and 10-6M), ZK191784 (10-8M and 10-6M) for 24 h. Effect of ZK159222 (A) and ZK191784 
(B) on phos-NF-κB p65 protein content was analysed using western blotting and quantified by 
densitometry. Data are means ± SEM, normalised to vinculin levels, n=3 per group. **P  < 0.01, ***P  
<  0.001 vs MC group.  
Figure 6. Effect of ZK159222 and ZK191784 on macrophage-induced secretion of IL-6, MCP-
1, IL-8 and RANTES by human adipocytes. Differentiated adipocytes were incubated with 
maintenance medium, 1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte 
medium was replaced with RPMI-1640 medium (control), MC medium or MC medium with 1,25-
(OH)2D3 (10-8M), ZK159222 (10-8M and 10-6M), ZK191784 (10-8M and 10-6M) for 24 h. Protein 
release of IL-6, MCP-1, IL-8 and RANTES was measured as protein concentrations in the culture 
medium using ELISAs. Results are expressed as means ± SEM, n=3 per group. γγγP < 0.001 vs 
RPMI control; *P < 0.05, **P < 0.01, ***P < 0.001 vs MC control and ††P < 0.01, †††P < 0.001 vs MC 
+ 1,25-dihydroxyvitamin D3. N.D. – not detected. MC only, macrophage-conditioned medium was 
used for measuring basal levels of the cytokine/chemokines released by macrophages. 
Figure 7. Cytotoxicity of macrophage-conditioned medium, 1,25-(OH)2D3, ZK159222 and 
ZK191784 in adipocytes. Differentiated adipocytes were incubated with maintenance medium, 
1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced 
with RPMI-1640 medium (control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M), 
ZK159222 (10-8M and 10-6M), ZK191784 (10-8M and 10-6M) for 24 h. Cytotoxicity was determined 
as LDH release into the cell culture medium. Data are expressed as means ± SEM, n=3 per group. 
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Figure. 1. ZK159222 reverses macrophage-inhibited IκBα expression by adipocytes. Differentiated 
adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or ZK159222 (10-8M and 10-
6M) for 48 h. Adipocyte medium was then replaced with RPMI-1640 medium (control), MC medium or MC 
medium with 1,25-(OH)2D3 (10-8M) or ZK159222 (10-8M and 10-6M) for 24 h. IκBα protein content was 
determined by western blotting and quantified by densitometry. Data are means ± SEM, normalised to 
vinculin levels, n=3 per group. **P  < 0.01 vs MC group.  
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Figure. 2. ZK159222 inhibits macrophage-induced expression of NF-κB p65 by adipocytes. Differentiated 
adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or ZK159222 (10-8M and 10-
6M) for 48 h. Adipocyte medium was then replaced with RPMI-1640 medium (control), MC medium or MC 
medium with 1,25-(OH)2D3 (10-8M) or ZK159222 (10-8M and 10-6M) for 24 h. Phos-NF-κB p65 protein content 
was analysed by western blotting and quantified by densitometry. Data are means ± SEM, normalised to 
vinculin levels, n=3 per group. *P  < 0.05, **P  < 0.01 vs MC group . 
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Figure. 3. Effects of ZK191784 on macrophage-inhibited expression of IκBα by adipocytes. Differentiated 
adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-
6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 medium (control), MC medium or MC 
medium with 1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) for 24 h. IκBα protein content was 
analysed by western blotting and quantified by densitometry. Data are means ± SEM, normalised to vinculin 
levels, n=3 per group. **P  < 0.01 vs MC group.  
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Figure. 4. Effects of ZK191784 on macrophage-induced expression of NF-κB p65 by adipocytes. 
Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or ZK191784 
(10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 medium (control), MC medium 
or MC medium with 1,25-(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) for 24 h. Phos-NF-κB p65 protein 
content was analysed by western blotting and quantified by densitometry. Data are means ± SEM, 
normalised to vinculin levels, n=3 per group. **P  < 0.05, **P  < 0.01, ***P  <  0.001 vs MC group.  
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 Figure. 5. ZK159222 and ZK191784 inhibit macrophage-induced expression of Phos-p38 MAPK by 
adipocytes. Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or 
ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 medium (control), 
MC medium or MC medium with 1,25-(OH)2D3 (10-8M), ZK159222 (10-8M and 10-6M), ZK191784 (10-8M and 
10-6M) for 24 h. Effect of ZK159222 (A) and ZK191784 (B) on phos-NF-κB p65 protein content was analysed 
using western blotting and quantified by densitometry. Data are means ± SEM, normalised to vinculin levels, 
n=3 per group. **P  < 0.01, ***P  <  0.001 vs MC group.  
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Figure. 6. Effect of ZK159222 and ZK191784 on macrophage-induced secretion of IL-6, MCP-1, IL-8 and 
RANTES by human adipocytes. Differentiated adipocytes were incubated with maintenance medium, 1,25-
(OH)2D3 (10-8M) or ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 
medium (control), MC medium or MC medium with 1,25-(OH)2D3 (10-8M), ZK159222 (10-8M and 10-6M), 
ZK191784 (10-8M and 10-6M) for 24 h. Protein release of IL-6, MCP-1 , IL-8 and RANTES was measured as 
protein concentrations in the culture medium using ELISAs. Results are expressed as means ± SEM, n=3 per 
group. γγγP < 0.001 vs RPMI control; *P < 0.05, **P < 0.01, ***P < 0.001 vs MC control and ††P < 0.01, †††P < 
0.001 vs MC + 1,25-dihydroxyvitamin D3. N.D. – not detected. MC only, macrophage-conditioned medium 
was used for measuring basal levels of the cytokine/chemokines released by macrophages. 
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Figure. 7. Cytotoxicity of macrophage-conditioned medium, 1,25-(OH)2D3, ZK159222 and ZK191784 in 
adipocytes. Differentiated adipocytes were incubated with maintenance medium, 1,25-(OH)2D3 (10-8M) or 
ZK191784 (10-8M and 10-6M) for 48 h. Adipocyte medium was replaced with RPMI-1640 medium (control), 
MC medium or MC medium with 1,25-(OH)2D3 (10-8M), ZK159222 (10-8M and 10-6M), ZK191784 (10-8M and 
10-6M) for 24 h. Cytotoxicity was determined as LDH release into the cell culture medium. Data are 
expressed as means ± SEM, n=3 per group. 
 
` 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
BARCHETTA, I., F. ANGELICO, ET AL. (2011). "STRONG ASSOCIATION BETWEEN NON ALCOHOLIC FATTY LIVER DISEASE 
(NAFLD) AND LOW 25(OH) VITAMIN D LEVELS IN AN ADULT POPULATION WITH NORMAL SERUM LIVER ENZYMES." BMC 
MED 9: 85. 
BOURLIER, V. AND A. BOULOUMIE (2009). "ROLE OF MACROPHAGE TISSUE INFILTRATION IN OBESITY AND INSULIN 
RESISTANCE." DIABETES METAB 35(4): 251-260. 
BOYLE, I. T., R. W. GRAY, ET AL. (1972). "RESPONSE OF INTESTINAL CALCIUM TRANSPORT TO 25-HYDROXY AND 1,25-
DIHYDROXY VITAMIN-D IN NEPHRECTOMIZED RATS." ENDOCRINOLOGY 90(3): 605-&. 
BROCK, K., W. Y. HUANG, ET AL. (2010). "LOW VITAMIN D STATUS IS ASSOCIATED WITH PHYSICAL INACTIVITY, OBESITY AND 
LOW VITAMIN D INTAKE IN A LARGE US SAMPLE OF HEALTHY MIDDLE-AGED MEN AND WOMEN." J STEROID BIOCHEM MOL 
BIOL 121(1-2): 462-466. 
CARLBERG, C. (2003). "MOLECULAR BASIS OF THE SELECTIVE ACTIVITY OF VITAMIN D ANALOGUES." JOURNAL OF CELLULAR 
BIOCHEMISTRY 88(2): 274-281. 
CHIANG, S. H., M. BAZUINE, ET AL. (2009). "THE PROTEIN KINASE IKK EPSILON REGULATES ENERGY BALANCE IN OBESE 
MICE." CELL 138(5): 961-975. 
CHIU, K. C., A. CHU, ET AL. (2004). "HYPOVITAMINOSIS D IS ASSOCIATED WITH INSULIN RESISTANCE AND BETA CELL 
DYSFUNCTION." AM J CLIN NUTR 79(5): 820-825. 
DING, C., D. GAO, ET AL. (2012). "VITAMIN D SIGNALLING IN ADIPOSE TISSUE." BRITISH JOURNAL OF NUTRITION 108(11): 
1915-1923. 
DING, C., J. P. WILDING, ET AL. (2013). "1,25-DIHYDROXYVITAMIN D3 PROTECTS AGAINST MACROPHAGE-INDUCED 
ACTIVATION OF NFKAPPAB AND MAPK SIGNALLING AND CHEMOKINE RELEASE IN HUMAN ADIPOCYTES." PLOS ONE 8(4): 
E61707. 
FAIN, J. N. (2006). "RELEASE OF INTERLEUKINS AND OTHER INFLAMMATORY CYTOKINES BY HUMAN ADIPOSE TISSUE IS 
ENHANCED IN OBESITY AND PRIMARILY DUE TO THE NONFAT CELLS." VITAM HORM 74: 443-477. 
FISH, E., G. BEVERSTEIN, ET AL. (2010). "VITAMIN D STATUS OF MORBIDLY OBESE BARIATRIC SURGERY PATIENTS." J SURG 
RES 164(2): 198-202. 
FONTANA, L., J. C. EAGON, ET AL. (2007). "VISCERAL FAT ADIPOKINE SECRETION IS ASSOCIATED WITH SYSTEMIC 
INFLAMMATION IN OBESE HUMANS." DIABETES 56(4): 1010-1013. 
GAO, D., M. MADI, ET AL. (2014). "INTERLEUKIN-1BETA MEDIATES MACROPHAGE-INDUCED IMPAIRMENT OF INSULIN 
SIGNALING IN HUMAN PRIMARY ADIPOCYTES." AM J PHYSIOL ENDOCRINOL METAB 307(3): E289-304. 
GAO, D., P. TRAYHURN, ET AL. (2010). "MACROPHAGE-SECRETED FACTORS INHIBIT ZAG EXPRESSION AND SECRETION BY 
HUMAN ADIPOCYTES." MOL CELL ENDOCRINOL 325(1-2): 135-142. 
GAO, D., P. TRAYHURN, ET AL. (2013). "1,25-DIHYDROXYVITAMIN D3 INHIBITS THE CYTOKINE-INDUCED SECRETION OF 
MCP-1 AND REDUCES MONOCYTE RECRUITMENT BY HUMAN PREADIPOCYTES." INT J OBES (LOND) 37(3): 357-365. 
GOLDNER, W. S., J. A. STONER, ET AL. (2008). "PREVALENCE OF VITAMIN D INSUFFICIENCY AND DEFICIENCY IN MORBIDLY 
OBESE PATIENTS: A COMPARISON WITH NON-OBESE CONTROLS." OBES SURG 18(2): 145-150. 
GREGOR, M. F. AND G. S. HOTAMISLIGIL (2011). "INFLAMMATORY MECHANISMS IN OBESITY." ANNU REV IMMUNOL 29: 
415-445. 
GUSTAFSON, B., A. HAMMARSTEDT, ET AL. (2007). "INFLAMED ADIPOSE TISSUE - A CULPRIT UNDERLYING THE METABOLIC 
SYNDROME AND ATHEROSCLEROSIS." ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 27(11): 2276-2283. 
HAUSSLER, M. R., P. W. JURUTKA, ET AL. (2011). "VITAMIN D RECEPTOR (VDR)-MEDIATED ACTIONS OF 1 
ALPHA,25(OH)(2)VITARNIN D-3: GENOMIC AND NON-GENOMIC MECHANISMS." BEST PRACTICE & RESEARCH CLINICAL 
ENDOCRINOLOGY & METABOLISM 25(4): 543-559. 
HERDICK, M., A. STEINMEYER, ET AL. (2000). "ANTAGONISTIC ACTION OF A 25-CARBOXYLIC ESTER ANALOGUE OF 1 
ALPHA,25-DIHYDROXYVITAMIN D-3 IS MEDIATED BY A LACK OF LIGAND-INDUCED VITAMIN D RECEPTOR INTERACTION WITH 
COACTIVATORS." JOURNAL OF BIOLOGICAL CHEMISTRY 275(22): 16506-16512. 
HERDICK, M., A. STEINMEYER, ET AL. (2000). "CARBOXYLIC ESTER ANTAGONISTS OF 1 ALPHA,25-DIHYDROXYVITAMIN D-3 
SHOW CELL-SPECIFIC ACTIONS." CHEMISTRY & BIOLOGY 7(11): 885-894. 
HII, C. S. AND A. FERRANTE (2016). "THE NON-GENOMIC ACTIONS OF VITAMIN D." NUTRIENTS 8(3). 
HOLICK, M. F. (2007). "VITAMIN D DEFICIENCY." NEW ENGLAND JOURNAL OF MEDICINE 357(3): 266-281. 
HOTAMISLIGIL, G. S. (2006). "INFLAMMATION AND METABOLIC DISORDERS." NATURE 444(7121): 860-867. 
HUCKINS, D., D. T. FELSON, ET AL. (1990). "TREATMENT OF PSORIATIC-ARTHRITIS WITH ORAL 1,25-DIHYDROXYVITAMIN-
D3 - A PILOT-STUDY." ARTHRITIS AND RHEUMATISM 33(11): 1723-1727. 
KAJIKAWA, M., H. ISHIDA, ET AL. (1999). "AN INSULINOTROPIC EFFECT OF VITAMIN D ANALOG WITH INCREASING 
INTRACELLULAR CA2+ CONCENTRATION IN PANCREATIC BETA-CELLS THROUGH NONGENOMIC SIGNAL TRANSDUCTION." 
ENDOCRINOLOGY 140(10): 4706-4712. 
KAMEI, N., K. TOBE, ET AL. (2006). "OVEREXPRESSION OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN ADIPOSE TISSUES 
CAUSES MACROPHAGE RECRUITMENT AND INSULIN RESISTANCE." J BIOL CHEM 281(36): 26602-26614. 
KANDA, H., S. TATEYA, ET AL. (2006). "MCP-1 CONTRIBUTES TO MACROPHAGE INFILTRATION INTO ADIPOSE TISSUE, INSULIN 
RESISTANCE, AND HEPATIC STEATOSIS IN OBESITY." J CLIN INVEST 116(6): 1494-1505. 
KEOPHIPHATH, M., C. ROUAULT, ET AL. (2010). "CCL5 PROMOTES MACROPHAGE RECRUITMENT AND SURVIVAL IN HUMAN 
ADIPOSE TISSUE." ARTERIOSCLER THROMB VASC BIOL 30(1): 39-45. 
KRISTIANSEN, O. P. AND T. MANDRUP-POULSEN (2005). "INTERLEUKIN-6 AND DIABETES: THE GOOD, THE BAD, OR THE 
INDIFFERENT?" DIABETES 54 SUPPL 2: S114-124. 
LIRA, F. S., J. C. ROSA, ET AL. (2011). "SUPPLEMENTING ALPHA-TOCOPHEROL (VITAMIN E) AND VITAMIN D3 IN HIGH FAT 
DIET DECREASE IL-6 PRODUCTION IN MURINE EPIDIDYMAL ADIPOSE TISSUE AND 3T3-L1 ADIPOCYTES FOLLOWING LPS 
STIMULATION." LIPIDS HEALTH DIS 10: 37. 
LOLMEDE, K., C. DUFFAUT, ET AL. (2011). "IMMUNE CELLS IN ADIPOSE TISSUE: KEY PLAYERS IN METABOLIC DISORDERS." 
DIABETES METAB 37(4): 283-290. 
LORENTE-CEBRIAN, S., A. ERIKSSON, ET AL. (2012). "DIFFERENTIAL EFFECTS OF 1ALPHA,25-DIHYDROXYCHOLECALCIFEROL 
ON MCP-1 AND ADIPONECTIN PRODUCTION IN HUMAN WHITE ADIPOCYTES." EUR J NUTR 51(3): 335-342. 
MARCOTORCHINO, J., E. GOURANTON, ET AL. (2012). "VITAMIN D REDUCES THE INFLAMMATORY RESPONSE AND RESTORES 
GLUCOSE UPTAKE IN ADIPOCYTES." MOL NUTR FOOD RES. 
MARTINESI, M., S. AMBROSINI, ET AL. (2014). "ROLE OF VITAMIN D DERIVATIVES IN INTESTINAL TISSUE OF PATIENTS WITH 
INFLAMMATORY BOWEL DISEASES." JOURNAL OF CROHNS & COLITIS 8(9): 1062-1071. 
MELLANBY, E. (1976). "NUTRITION CLASSICS. THE LANCET 1:407-12, 1919. AN EXPERIMENTAL INVESTIGATION OF RICKETS. 
EDWARD MELLANBY." NUTR REV 34(11): 338-340. 
MENEGAZ, D., A. BARRIENTOS-DURAN, ET AL. (2010). "1 ALPHA,25(OH)(2)-VITAMIN D-3 STIMULATION OF SECRETION VIA 
CHLORIDE CHANNEL ACTIVATION IN SERTOLI CELLS." JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY 119(3-
5): 127-134. 
MIZWICKI, M. T. AND A. W. NORMAN (2009). "THE VITAMIN D STEROL-VITAMIN D RECEPTOR ENSEMBLE MODEL OFFERS 
UNIQUE INSIGHTS INTO BOTH GENOMIC AND RAPID-RESPONSE SIGNALING." SCIENCE SIGNALING 2(75). 
MOLINARI, C., M. RIZZI, ET AL. (2013). "1 ALPHA, 25-DIHYDROXYCHOLECALCIFEROL (VITAMIN D3) INDUCES NO-
DEPENDENT ENDOTHELIAL CELL PROLIFERATION AND MIGRATION IN A THREE-DIMENSIONAL MATRIX." CELLULAR 
PHYSIOLOGY AND BIOCHEMISTRY 31(6): 815-822. 
MUTT, S. J., T. KARHU, ET AL. (2012). "INHIBITION OF CYTOKINE SECRETION FROM ADIPOCYTES BY 1,25-DIHYDROXYVITAMIN 
D(3) VIA THE NF-KAPPAB PATHWAY." FASEB J 26(11): 4400-4407. 
NEELS, J. G., L. BADEANLOU, ET AL. (2009). "KERATINOCYTE-DERIVED CHEMOKINE IN OBESITY: EXPRESSION, REGULATION, 
AND ROLE IN ADIPOSE MACROPHAGE INFILTRATION AND GLUCOSE HOMEOSTASIS." J BIOL CHEM 284(31): 20692-20698. 
NIJENHUIS, T., B. C. VAN DER EERDEN, ET AL. (2006). "THE NOVEL VITAMIN D ANALOG ZK191784 AS AN INTESTINE-
SPECIFIC VITAMIN D ANTAGONIST." FASEB J 20(12): 2171-2173. 
OLSON, M. L., N. M. MAALOUF, ET AL. (2012). "VITAMIN D DEFICIENCY IN OBESE CHILDREN AND ITS RELATIONSHIP TO 
GLUCOSE HOMEOSTASIS." J CLIN ENDOCRINOL METAB 97(1): 279-285. 
POLLY, P., M. HERDICK, ET AL. (2000). "VDR-ALIEN: A NOVEL, DNA-SELECTIVE VITAMIN D-3 RECEPTOR-COREPRESSOR 
PARTNERSHIP." FASEB JOURNAL 14(10): 1455-1463. 
ROTTER, V., I. NAGAEV, ET AL. (2003). "INTERLEUKIN-6 (IL-6) INDUCES INSULIN RESISTANCE IN 3T3-L1 ADIPOCYTES AND IS, 
LIKE IL-8 AND TUMOR NECROSIS FACTOR-ALPHA, OVEREXPRESSED IN HUMAN FAT CELLS FROM INSULIN-RESISTANT SUBJECTS." 
J BIOL CHEM 278(46): 45777-45784. 
SCHMITZ, A. A., S. HACKETHAL, ET AL. (2015). "SHARING PHARMA COMPOUNDS WITH ACADEMIA: EXPERIENCES WITH 
PROVIDING VITAMIN D RECEPTOR LIGANDS." NATURE REVIEWS DRUG DISCOVERY 14(4). 
SLATOPOLSKY, E. AND A. J. BROWN (2002). "VITAMIN D ANALOGS FOR THE TREATMENT OF SECONDARY 
HYPERPARATHYROIDISM." BLOOD PURIFICATION 20(1): 109-112. 
SMITH, D. C., C. S. JOHNSON, ET AL. (1999). "A PHASE I TRIAL OF CALCITRIOL (1,25-DIHYDROXYCHOLECALCIFEROL) IN 
PATIENTS WITH ADVANCED MALIGNANCY." CLINICAL CANCER RESEARCH 5(6): 1339-1345. 
STRAUCH, U. G., F. OBERMEIER, ET AL. (2007). "CALCITRIOL ANALOG ZK191784 AMELIORATES ACUTE AND CHRONIC 
DEXTRAN SODIUM SULFATE-INDUCED COLITIS BY MODULATION OF INTESTINAL DENDRITIC CELL NUMBERS AND PHENOTYPE." 
WORLD JOURNAL OF GASTROENTEROLOGY 13(48): 6529-6537. 
SUN, L. AND G. CARPENTER (1998). "EPIDERMAL GROWTH FACTOR ACTIVATION OF NF-KAPPA B IS MEDIATED THROUGH I 
KAPPA B ALPHA DEGRADATION AND INTRACELLULAR FREE CALCIUM." ONCOGENE 16(16): 2095-2102. 
TAK, P. P. AND G. S. FIRESTEIN (2001). "NF-KAPPAB: A KEY ROLE IN INFLAMMATORY DISEASES." J CLIN INVEST 107(1): 7-
11. 
THURINGER, D., A. HAMMANN, ET AL. (2011). "TRANSACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR BY 
HEAT SHOCK PROTEIN 90 VIA TOLL-LIKE RECEPTOR 4 CONTRIBUTES TO THE MIGRATION OF GLIOBLASTOMA CELLS." JOURNAL 
OF BIOLOGICAL CHEMISTRY 286(5): 3418-3428. 
TOELL, A., M. M. GONZALEZ, ET AL. (2001). "DIFFERENT MOLECULAR MECHANISMS OF VITAMIN D-3 RECEPTOR 
ANTAGONISTS." MOLECULAR PHARMACOLOGY 59(6): 1478-1485. 
VAISANEN, S., M. PERAKYLA, ET AL. (2002). "CRITICAL ROLE OF HELIX 12 OF THE VITAMIN D-3 RECEPTOR FOR THE PARTIAL 
AGONISM OF CARBOXYLIC ESTER ANTAGONISTS." JOURNAL OF MOLECULAR BIOLOGY 315(2): 229-238. 
WATSON, K. E., M. L. ABROLAT, ET AL. (1997). "ACTIVE SERUM VITAMIN D LEVELS ARE INVERSELY CORRELATED WITH 
CORONARY CALCIFICATION." CIRCULATION 96(6): 1755-1760. 
WAUGH, D. J. AND C. WILSON (2008). "THE INTERLEUKIN-8 PATHWAY IN CANCER." CLIN CANCER RES 14(21): 6735-
6741. 
ZHANG, Y., D. Y. LEUNG, ET AL. (2012). "VITAMIN D INHIBITS MONOCYTE/MACROPHAGE PROINFLAMMATORY CYTOKINE 
PRODUCTION BY TARGETING MAPK PHOSPHATASE-1." J IMMUNOL 188(5): 2127-2135. 
ZUGEL, U., A. STEINMEYER, ET AL. (2002). "A NOVEL IMMUNOSUPPRESSIVE 1 ALPHA,25-DIHYDROXYVITAMIN D-3 ANALOG 
WITH REDUCED HYPERCALCEMIC ACTIVITY." JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(6): 1434-1442. 
 
 
 
